东北制药2024年增利不增收，副总经理冯晓薪酬256万元高于董事长

Core Viewpoint - Northeast Pharmaceutical (SZ000597) reported a decrease in revenue for 2024, while net profit increased, indicating a mixed financial performance for the year [1]. Financial Performance - In 2024, Northeast Pharmaceutical achieved operating revenue of 7.50 billion yuan, a decrease of 8.98% compared to 2023 [2]. - The net profit attributable to shareholders was 409.85 million yuan, an increase of 14.34% year-on-year [2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 311.65 million yuan, up 18.97% from the previous year [2]. - The net cash flow from operating activities was 758.76 million yuan, reflecting a significant increase of 29.32% [2]. - Basic and diluted earnings per share were both 0.29 yuan, representing a 16.00% increase [2]. - The weighted average return on equity was 8.02%, up from 7.65% in 2023 [2]. Asset and Equity Position - Total assets at the end of 2024 were 14.45 billion yuan, down 5.42% from the previous year [2]. - The net assets attributable to shareholders increased to 5.32 billion yuan, a rise of 6.68% compared to 2023 [2]. Employee Statistics - As of the end of 2024, the total number of employees at Northeast Pharmaceutical was 5,964, a decrease of 250 employees or 4.02% from the previous year [2]. Executive Compensation - In 2024, three executives received salaries exceeding one million yuan, with the highest being 2.56 million yuan for the Deputy General Manager [4].